| Literature DB >> 35910346 |
Rishi Man Chugh1, Pooja Mittal2, Namratha Mp3, Tanu Arora1, Tanima Bhattacharya4,5, Hitesh Chopra6, Simona Cavalu7, Rupesh K Gautam8.
Abstract
Fungi are extremely diverse in terms of morphology, ecology, metabolism, and phylogeny. Approximately, 130 medicinal activities like antitumor, immunomodulation, antioxidant, radical scavenging, cardioprotective and antiviral actions are assumed to be produced by the various varieties of medicinal mushrooms. The polysaccharides, present in mushrooms like β-glucans, micronutrients, antioxidants like glycoproteins, triterpenoids, flavonoids, and ergosterols can help establish natural resistance against infections and toxins.. Clinical trials have been performed on mushrooms like Agaricus blazei Murrill Kyowa for their anticancer effect, A. blazei Murrill for its antihypertensive and cardioprotective effects, and some other mushrooms had also been evaluated for their neurological effects. The human evaluation dose studies had been also performed and the toxicity dose was evaluated from the literature for number of mushrooms. All the mushrooms were found to be safe at a dose of 2000 mg/kg but some with mild side effects. The safety and therapeutic effectiveness of the fungal mushrooms had shifted the interest of biotechnologists toward fungal nanobiotechnology as the drug delivery system due to the vast advantages of nanotechnology systems. In complement to the vital nutritional significance of medicinal mushrooms, numerous species have been identified as sources of bioactive chemicals. Moreover, there are unanswered queries regarding its safety, efficacy, critical issues that affect the future mushroom medicine development, that could jeopardize its usage in the twenty-first century.Entities:
Keywords: Medicinal mushrooms; antiviral; cardioprotective; immune boosters; immunomodulation; radical scavenging
Year: 2022 PMID: 35910346 PMCID: PMC9328747 DOI: 10.3389/fphar.2022.925387
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.988
Various medicinal mushrooms derived Polysaccharides and polysaccharide-protein complexes which are immunomodulatory.
| Source | Active compound | Immunomodulatory effect | References |
|---|---|---|---|
|
| 3-D-glucan, AF1 β-1 main chain with the two β-1,6-Dglucosyl residues | Produces cancer cell apoptosis |
|
|
| The glycoprotein, Flammulina velutipes peptidoglycan (FVP), β1,3-D-glucan | Secrete Tumor necrosis factor alpha (TNF-α), Interleukin production |
|
|
| Glucan | Induces the splenocytes and thymocytes |
|
|
| β-Glucan | Promote Interferon gamma (IFN-γ) and Interleukin-6 (IL-6) synthesis |
|
|
| Acidic glucuronoxylomannan of an α-1,3-D-mannan with | Human monocytes synthesized |
|
The immunoregulatory effects of lectins found in medicinal mushrooms.
| Source | Lectin Name | Immunomodulatory Effect | References |
|---|---|---|---|
|
| Agrocybe aegerita lectin (AAL) | Inhibits the proliferation of HL60 SW480, 4T1, HeLa, MGC803, BGC823, SGC7901, and S180 cells |
|
|
| Boletus edulis lectin (BEL) | Induces splenocyte mitogenicity in mice and inhibits the growth of human hepatocyte carcinoma HT-29 and G2 cells |
|
|
| Grifola frondosa lectin (GFL) | Inhibits the HeLa acceleration |
|
|
| Russula lepida lectin (RLL) | Inhibits the build-up of 2 MCF7 cells and HepG |
|
|
| Xylaria hypoxylon lectin (XHL | Inhibits the propagation of HepG2 cells |
|
The immunoregulatory effects of FIPs found in medicinal mushrooms.
| FIP Name | Source | Immunomodulatory effect | References |
|---|---|---|---|
| FIPcru1 |
| Vital growth of the murine splenocytes increases secretion of IL-2 |
|
| FIP-gmi |
| Controls the TNF-α |
|
FIGURE 1Various triterpenoids derivatives (A) Ganoderic acid A300 (B) Ganoderic acid E300 (C) Ganoderic acid gamma 300 (D) Ganodermanontriol 300.
Biological activities of various mushroom extracts and mechanism of action.
| Extract Sources | Target Cancer Cells | Mode of Action | References |
|---|---|---|---|
|
| Breast | Inhibits the stimulation of caspase-3 and aromatase activity |
|
|
| Colon | Stimulates the immune system |
|
|
| Uterus, leukemia, ovary, prostate | Inhibition of the telomerase activity, initiates the cytochrome c release, caspase activity, control of Bcl-2 synthesis |
|
|
| Hepatoma and breast | Inhibits the NF-κB factor |
|
|
| Hepatoma, leukemia, breast | Initiation of IFN-γ,IL-18 |
|
|
| Hepatoma and Colon | Suppress the NF-κB factor |
|
|
| Breast, colon cervix | Arresting cell cycle |
|
|
| Cervix, colon, prostate adenocarcinoma, lung, stomach | Stimulates the TNF- γ, caspase activation, inhibits the matrix metalloproteinase expression, suppression of transcription factor AP-1 |
|
|
| Colon | Activates the macrophages, natural killer cells, and angiogenesis inhibition |
|
|
| Cervix, colon | Antioxidative |
|
|
| Bladder, breast, liver hepatoma,, stomach lung | Induces IL-12, IFN-γ, synthesis of TNF-α, T- and macrophage, CD4+-, the proliferation of the dendritic cell, activation of a natural killer cell, an increase of thymus mass and plasma immunoglobulin receptors, spleen, reduces the epidermal growth factor receptors |
|
|
| Cervix, colon | Antioxidative activity |
|
|
| Cervix, colon | Increases the cytokines, antioxidative activity |
|
|
| Cervix, hepatoma | Antioxidative activity |
|
|
| Cervix, colon, melanoma, leukemia, lung, lymphoma, prostate, stomach | Antioxidative activity, antimutagenic activity |
|
FIGURE 2Pathway depicting the role of medicinal mushrooms in prevention of cardiovascular diseases.
Antihypertensive mechanism and bio components from the edible mushrooms.
| Component | Mode of Mechanism | Source | References |
|---|---|---|---|
| Tripeptide 3,3,5,5tetramethyl- 4piperidone (TMP) | Partial ganglionic blocking mediated path |
|
|
| Vasodilation |
|
| |
| D-mannitol | Inhibits the ACE rapidly |
|
|
| Oligopeptides | Inhibits the ACE rapidly |
|
|
| Potassium | Hyperpolarizes the Kir channels and/or Na + −pump |
|
|
| Lentinan | Vasodilation |
|
|
| Pentapeptide | Competitive and stereoselective |
|
|
|
| Inhibition of ACE |
|
|
| Hexapeptide | Inhibition of ACE |
|
|
| Maleic/succinic acid derivatives, triterpenoids, benzenoids, and benzoquinone derivatives | Reduces the growth and phosphorylation of PKC in phorbol- 12,13dibutyrate (PDBu)activated platelets |
|
|
| Oligo peptides, protein extract | Inhibition of ACE |
|
|